ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Family History of Early Onset or Lethal Prostate Cancer and the Risk of Prostate Cancer Death in Sweden.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundA family history (FH) of prostate cancer increases the risk of prostate cancer, but its association with prostate cancer mortality remains unclear.
methodsFH was defined as having a first-degree relative who was diagnosed before age 60 or died from prostate cancer. We used Cox regression to estimate associations between FH and prostate cancer characteristics at diagnosis, radical treatment, and prostate cancer death in men born after 1932 and diagnosed with prostate cancer between 1998 and 2020 in Sweden.
resultsAmong 125,272 men with prostate cancer, 13,193 had an FH of early onset or lethal prostate cancer. At diagnosis, men with FH had 1.4 years lower median age, 0.87 ng/mL lower serum PSA, lower proportion of Gleason score 8 to 10 cancer (14.8% vs. 17.6%), lower odds for metastatic disease [OR, 0.79; 95% confidence interval (CI), 0.73-0.86], and higher odds for radical treatment (OR, 1.25; 95% CI, 1.18-1.32). With a median follow-up of 6.9 years and 12,773 prostate cancer deaths, mortality was lower (crude HR, 0.77; 95% CI, 0.73-0.82) in men with FH. Adjustment for prostate cancer characteristics attenuated this association (adjusted HR, 0.94; 95% CI, 0.88-1.00).
conclusionsMen with prostate cancer and an FH of early onset or lethal prostate cancer had more favorable cancer characteristics, a higher likelihood of radical treatment, and similar prostate cancer mortality compared with men without an FH. IMPACT: In men with prostate cancer, the risk of prostate cancer death seems unaffected by an FH of early onset or lethal prostate cancer after controlling for clinical characteristics. More research is needed on the potential role of screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.